Baird maintained an Outperform rating and $100 price target on Apellis Pharmaceuticals following an “expected” negative opinion for approval for pegcetacoplan from the EU’s CHMP, or Committee for Medicinal Products for Human Use. While the analyst sees “some chance” the appeal process could flip the CHMP vote positive in Q4, the firm believes the probability is low.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
- Beam Therapeutics Stock (NASDAQ:BEAM): The Future of Gene Editing?
- Apellis announces SYFOVRE preserved visual function at 36 months in GALE study
- Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
- Apellis initiated with a Neutral at Piper Sandler